RxDoctor Payments Data

Jennie Webb, PA

Physician Assistant · Waterbury, CTNPI 1912495797

Payments from drug & device makers

$1,640in general payments, 2019–2025

Across 66 payments — averaging $24.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Bayer$220
  • AbbVie$79
  • Boehringer Ingelheim$69
  • AstraZeneca$49
  • Astellas Pharma US Inc$34
  • plus $123 from 6 others

What the payments were for

  • Food & beverage$1,61799%
  • Education$231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,640 in reported general payments places this provider in the 85th percentile of 1,795 physician assistant providers in Connecticut.

See all physician assistant providers in Connecticut

Medicare billing

Part B allowed, 2024
$25,650
Medicare patients
134
Services billed
279

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide64$76,497
JardianceEmpagliflozin32$43,500
FarxigaDapagliflozin Propanediol24$39,356
EliquisApixaban32$29,383
JanuviaSitagliptin Phosphate28$27,695
LinzessLinaclotide33$26,581
Tresiba Flextouch U-100Insulin Degludec28$13,885
Breo ElliptaFluticasone/Vilanterol33$13,352
VascepaIcosapent Ethyl23$9,521
SynjardyEmpagliflozin/Metformin Hcl13$9,184
Praluent PenAlirocumab12$8,893
Dexlansoprazole DrDexlansoprazole11$3,182
Rosuvastatin Calcium132$2,443
Albuterol Sulfate HfaAlbuterol Sulfate73$1,975
Gabapentin61$1,441

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,065$76,49764 claims
Boehringer IngelheimJardiance, Synjardy$69$52,68445 claims
AstraZenecaFarxiga$49$39,35624 claims
PfizerEliquis$22$29,38332 claims
AbbVieLinzess, Synthroid$79$27,76952 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,795 physician assistant providers in Connecticut.

Other physician assistant in Waterbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →